Biocon Ltd

'Raising of funds by way of issuance any instrument or security, including equity shares, non-convertible debt instruments along with warrants, any other convertible securities or any other eligible securities or any combination thereof by way of qualified institutions placement(s), rights issue, preferential allotment or private placement(s) and/or any combination thereof or any other method as may be permitted under applicable laws, and on such terms and conditions as may be considered appropriate by the board in its absolute discretion under applicable laws, for an aggregate amount of up to Rs 4,500 crore, in one or more tranches and/or one or more issuances, subject to the receipt of necessary approvals including approval of the shareholders of the company and other regulatory / statutory approvals,' it stated in exchange filing. Meanwhile, the company's board also approved to increase authorized share capital from existing Rs 625 crore divided into 125 crore equity shares of Rs 5 each to Rs 700 crore divided into 140 crore equity shares of Rs 5 each, subject to the receipt of necessary approvals including approval of the shareholders of the company and other regulatory / statutory approvals. Biocon is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. The company's consolidated net profit declined 96.2% to Rs 25.10 crore in Q3 FY25 as compared with Rs 660 crore in Q3 FY24. Net sales increased 6.3% to Rs 3773 crore in Q3 FY25. The counter rose 0.57% to end at Rs 335.85 on Wednesday, 23 April 2025.Powered by Capital Market - Live

The Board of Biocon at its meeting held on 23 April 2025 has approved raising of funds up to Rs 4,500 crore by way of issue of securities, in one or more tranches. The Board also approved increase in authorised share capital from Rs 625 crore to Rs 700 crore (dividend into 1,40,00,00,000 equity shares of Rs 5 each). Powered by Capital Market - Live

Biocon will hold a meeting of the Board of Directors of the Company on 23 April 2025.Powered by Capital Market - Live

Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for treating a range of ophthalmology conditions. The biosimilar references Regeneron's blockbuster drug EYLEA, a widely prescribed treatment in the U.S. for retinal diseases. As part of the settlement, Biocon Biologics and Regeneron agreed to dismiss ongoing litigation related to U.S. patent no. US11084865. This includes the pending appeal at the United States Court of Appeals for the Federal Circuit and the case in the U.S. District Court for the Northern District of West Virginia, Clarksburg Division. While the financial and commercial terms of the settlement remain confidential, the agreement enables Biocon Biologics to potentially commercialize Yesafili in the U.S. starting in the second half of 2026'or earlier, depending on certain conditions. The company has also secured a Canadian launch deal for Yesafili no later than 1 July 2025. Shreehas Tambe, CEO & managing director, Biocon Biologics, said: This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality aflibercept biosimilar to patients and healthcare providers in the United States. As the first-to-file interchangeable biosimilar to Eylea, YESAFILI affirms our scientific strength and marks our strategic entry into Ophthalmology, expanding our footprint in the U.S. and advancing our mission to increase access to life-changing treatments. Biocon is an innovation-led global biopharmaceuticals company. On a consolidated basis, its net profit slumped 96.20% to Rs 25.10 crore while net sales rose 6.32% to Rs 3773 crore in Q3 December 2024 over Q3 December 2023. Powered by Capital Market - Live

This drug is used to treat multiple cancers by inhibiting VEGF (vascular endothelial growth factor), effectively cutting off blood supply to tumors. This marks Biocon's seventh biosimilar approval in the U.S., expanding its oncology arsenal alongside OGIVRI (trastuzumab) and FULPHILA (pegfilgrastim). JOBEVNE is already being sold in Europe and Canada under the name ABEVMY. CEO Shreehas Tambe hailed the approval as a testament to Biocon's scientific strength and mission to make affordable biologics widely available. With U.S. sales of bevacizumab hitting ~$2 billion in 2023, JOBEVNE has blockbuster potential. Biocon is a global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. On a consolidated basis, Biocon's net profit slumped 96.20% to Rs 25.10 crore while net sales rose 6.32% to Rs 3773 crore in Q3 December 2024 over Q3 December 2023. Shares of Biocon dropped 5.33% to Rs 305.20 on Wednesday, 9 April 2025. The Indian stock market is shut today for Shri Mahavir Jayanti. Powered by Capital Market - Live

The Board of Biocon at its meeting held on 04 April 2025 has approved issuance of Commercial Papers up to an amount not exceeding Rs. 600 crore in one or more tranches on private placement basis. Powered by Capital Market - Live

Biocon will hold a meeting of the Board of Directors of the Company on 8 May 2025.Powered by Capital Market - Live

Biocon will hold a meeting of the Board of Directors of the Company on 4 April 2025.Powered by Capital Market - Live

The announcement was made after market hours yesterday. Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. The company had reported a consolidated net profit of Rs 25 crore in Q3 FY25, which is significantly lower as compared with the PAT of Rs 660 crore posted in Q3 FY24. Revenue from operations fell by 3% YoY to Rs 3,821 crore during the period under review. The scrip shed 0.60% to end at Rs 339.15 on Tuesday, 1 April 2025.Powered by Capital Market - Live

The key domestic indices traded with substantial gains in morning trade. The Nifty traded near 23,550 mark. Realty shares witnessed buying demand for the fifth consecutive trading session. At 10:26 IST, the barometer index, the S&P BSE Sensex, added 647.43 points or 0.84% to 77,553.07. The Nifty 50 index advanced 198.25 points or 0.85% to 23,548.55. The broader market broader market outperformed the frontline indices. The S&P BSE Mid-Cap index rose 1.15% and the S&P BSE Small-Cap index added 1.29%. The market breadth was strong. On the BSE, 2,760 shares rose and 998 shares fell. A total of 198 shares were unchanged. Buzzing Index: The Nifty Realty index jumped 1.85% to 879.55. The index surged 10.34% in the five consecutive trading sessions. Brigade Enterprises (up 4.87%), Macrotech Developers (up 4.59%), Oberoi Realty (up 1.97%), Prestige Estates Projects (up 1.9%) and Phoenix Mills (up 1.59%), Mahindra Lifespace Developers (up 1.15%), Raymond (up 1.11%), Godrej Properties (up 0.81%) and DLF (up 0.34%) surged. Stocks in Spotlight: Biocon added 1.16% after the company's wholly owned subsidiary Biocon Pharma announced the receipt of U.S Food and Drug Administration (US FDA) approval for its ANDA Norepinephrine Bitartrate Injection. RailTel Corporation of India surged 8.49% after the company announced that it had received a work order worth Rs 25.15 crore from Hindustan Petroleum Corporation (HPCL). NCC added 2.21% after the company announced that it has received a Letter of Acceptance (LoA) worth Rs 1,480.34 crore from the Bihar Medical Services & Infrastructure Corporation.Powered by Capital Market - Live